<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23838466</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV.</ArticleTitle><Pagination><StartPage>2378</StartPage><EndPage>2385</EndPage><MedlinePgn>2378-85</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25639</ELocationID><Abstract><AbstractText>Combination vaccines can reduce the number of injections and simplify the immunization schedule required to prevent different diseases. Here we assessed the immunogenicity in a mouse model of a vaccine composition comprising inactivated influenza viruses (H5N1/H1N1), enterovirus 71 (EV71), and/or Japanese encephalitis virus (JEV) and investigated whether the vaccine formulations can overcome the immunologic interference between the individual vaccine components. We demonstrated that the antigenic competition happens between H5N1/H1N1 or H5N1/EV71 inactivated virions when the vaccine combinations either formulated with Alum suspensions or without adjuvant. In the presence of PELC emulsified particles, EV71-specific immune responses before and after incorporating H5N1 virus into EV71 vaccine were detected of no significant difference; in addition, H5N1- and EV71-specific immune responses were found at the same level when H5N1/EV71/JEV consolidating into combination vaccine. Emulsified vaccine formulation was represented as a potential tool that is found to reduce the number of injections required to prevent multiple infectious strains causing the same disease (H5N1/H1N1) and/or that protect against different diseases (H5N1/EV71). Combination vaccines can also include a third component to protect against H5N1/EV71/JEV at the same time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology; National Health Research Institutes; Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ching-Yun</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Lin</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shih-Chang</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chien-Chun</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jui-Yuan</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Alan Yung-Chih</ForeName><Initials>AY</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tsung-Chun</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Ai-Hsiang</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming-Hsi</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000534">Alum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004655">Emulsions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>34S289N54E</RegistryNumber><NameOfSubstance UI="C041524">aluminum sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000534" MajorTopicYN="N">Alum Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004664" MajorTopicYN="N">Encephalitis Virus, Japanese</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Japanese encephalitis</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">combination vaccine</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">influenza</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23838466</ArticleId><ArticleId IdType="pmc">PMC3981847</ArticleId><ArticleId IdType="doi">10.4161/hv.25639</ArticleId><ArticleId IdType="pii">25639</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Center for Immunization and Respiratory Diseases General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60:1&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21293327</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) MMWR Recomm Rep. 1999;48:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848294</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Recommended immunization schedules for persons aged 0-18 years-United States 2012. MMWR QuickGuide. 2012;61:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22451974</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) Pediatrics. 1999;103:1064&#x2013;77. doi: 10.1542/peds.103.5.1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.103.5.1064</ArticleId><ArticleId IdType="pubmed">10224194</ArticleId></ArticleIdList></Reference><Reference><Citation>Spier RE. Multivalent vaccines: prospects and challenges. Folia Microbiol (Praha) 1997;42:105&#x2013;12. doi: 10.1007/BF02898716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02898716</ArticleId><ArticleId IdType="pubmed">9306653</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006;27:573&#x2013;9. doi: 10.1016/j.it.2006.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2006.10.005</ArticleId><ArticleId IdType="pubmed">17049307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462:449&#x2013;60. doi: 10.1038/nature08604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08604</ArticleId><ArticleId IdType="pubmed">19940915</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant--&#x2018;the long and winding road&#x2019;. Drug Discov Today. 2009;14:541&#x2013;51. doi: 10.1016/j.drudis.2009.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2009.02.009</ArticleId><ArticleId IdType="pubmed">19508916</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO recommendations on pandemic (H1N1) 2009 vaccines. Geneva: Pandemic (H1N1) briefing note 2. Accessed 2009 Jul 13. Available: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/</Citation></Reference><Reference><Citation>Huang MH, Huang CY, Lin SC, Chen JH, Ku CC, Chou AH, et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect. 2009;11:654&#x2013;60. doi: 10.1016/j.micinf.2009.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2009.03.003</ArticleId><ArticleId IdType="pubmed">19344782</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, Liao CC, et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One. 2010;5:e12279. doi: 10.1371/journal.pone.0012279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012279</ArticleId><ArticleId IdType="pmc">PMC2924384</ArticleId><ArticleId IdType="pubmed">20808862</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000;18:1755&#x2013;62. doi: 10.1016/S0264-410X(99)00526-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(99)00526-5</ArticleId><ArticleId IdType="pubmed">10699323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6:e20005. doi: 10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A. 2011;108:11169&#x2013;74. doi: 10.1073/pnas.1107941108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1107941108</ArticleId><ArticleId IdType="pmc">PMC3131326</ArticleId><ArticleId IdType="pubmed">21690334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18:274&#x2013;80. doi: 10.1038/nm.2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2612</ArticleId><ArticleId IdType="pubmed">22286307</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20689501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelso A. CD4+ T cells limit the damage in influenza. Nat Med. 2012;18:200&#x2013;2. doi: 10.1038/nm.2654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2654</ArticleId><ArticleId IdType="pubmed">22310682</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Japanese encephalitis vaccines. Wkly Epidemiol Rec. 2006;81:331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">16933380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Hsu FK, Hsu LC. Current development and use of Japanese encephalitis vaccine. Taiwan Epidemiol Bull. 2013;29:129&#x2013;41.</Citation></Reference><Reference><Citation>Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, et al. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan. J Microbiol Immunol Infect. 2012:S1684&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">23022464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Yuan CJ, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8:1&#x2013;9. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One. 2012;7:e34834. doi: 10.1371/journal.pone.0034834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034834</ArticleId><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CY, Lin CW, Chiang CK, Chen PL, Huang CY, et al. Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence. ACS Med Chem Lett. 2013;4:522&#x2013;6. doi: 10.1021/ml400081f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml400081f</ArticleId><ArticleId IdType="pmc">PMC4027239</ArticleId><ArticleId IdType="pubmed">24900703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>